Synthesis and Characterisation of Novel Tricyclic and Tetracyclic Furoindoles: Biological Evaluation as SAHA Enhancer against Neuroblastoma and Breast Cancer Cells.
Breast Neoplasms
/ drug therapy
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Drug Synergism
Female
Heterocyclic Compounds
/ chemical synthesis
Histone Deacetylase Inhibitors
/ pharmacology
Humans
Ketones
/ chemical synthesis
MCF-7 Cells
Neuroblastoma
/ drug therapy
Vorinostat
/ pharmacology
HDAC inhibitors
SAHA enhancement
breast cancer
furoindole
neuroblastoma
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
22 Sep 2021
22 Sep 2021
Historique:
received:
10
08
2021
revised:
08
09
2021
accepted:
14
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
18
11
2021
Statut:
epublish
Résumé
The dihydropyranoindole structures were previously identified as promising scaffolds for improving the anti-cancer activity of histone deacetylase inhibitors. This work describes the synthesis of related furoindoles and their ability to synergize with suberoylanilide hydroxamic acid (SAHA) against neuroblastoma and breast cancer cells. The nucleophilic substitution of hydroxyindole methyl esters with α-haloketones yielded the corresponding arylether ketones, which were subsequently cyclized to tricyclic and tetracyclic furoindoles. The furoindoles showed promising individual cytotoxic efficiency against breast cancer cells, as well as decent SAHA enhancement against cancer cells in select cases. Interestingly, the best IC
Identifiants
pubmed: 34641289
pii: molecules26195745
doi: 10.3390/molecules26195745
pmc: PMC8510456
pii:
doi:
Substances chimiques
Heterocyclic Compounds
0
Histone Deacetylase Inhibitors
0
Ketones
0
Vorinostat
58IFB293JI
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Health and Medical Research Council
ID : APP1016699
Références
J Med Chem. 2007 Mar 8;50(5):901-14
pubmed: 17290978
Cancer Res. 2001 May 1;61(9):3591-4
pubmed: 11325825
Invest New Drugs. 2005 Mar;23(2):99-109
pubmed: 15744585
J Clin Oncol. 2005 Jun 10;23(17):3923-31
pubmed: 15897550
J Thorac Cardiovasc Surg. 2004 Nov;128(5):740-8
pubmed: 15514602
Cancer Res. 2002 Nov 1;62(21):6108-15
pubmed: 12414635
J Am Chem Soc. 2006 Jun 7;128(22):7136-7
pubmed: 16734447
Cancer Chemother Pharmacol. 2011 Mar;67(3):705-15
pubmed: 20512578
Surgery. 2005 Aug;138(2):360-7
pubmed: 16153448
Oncogene. 2021 Apr;40(13):2367-2381
pubmed: 33658627
Clin Cancer Res. 2007 Apr 15;13(8):2318-22
pubmed: 17438089
Clin Lung Cancer. 2006 Jan;7(4):257-61
pubmed: 16512979
Oncogene. 2007 Feb 26;26(9):1351-6
pubmed: 17322921
Molecules. 2020 Mar 18;25(6):
pubmed: 32197360